EXACTUS, INC. (OTCMKTS:EXDI) Files An 8-K Unregistered Sales of Equity Securities

EXACTUS, INC. (OTCMKTS:EXDI) Files An 8-K Unregistered Sales of Equity Securities
Item 3.02Unregistered Sales of Equity Securities.

Story continues below

Issuance of Additional Common Stock In Private Offering

As disclosed in our Current Reports on Form 8-K filed February 21, 2019, February 28, 2019, and March 6, 2019, we have previously accepted subscriptions of $2,132,253 for a total of 82,650,143 shares of Common Stock, or approximately 10,331,268 shares following the recent effectiveness of our 1 for 8 reverse split of our Common Stock. On March 13, 2019 we accepted additional subscriptions in the total amount $891,000 for an additional 4,140,206 shares of Common Stock. The offer and sale of these shares was made solely to “Accredited Investors” as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933 (the “Securities Act”). We engaged in no general solicitation or advertising with regard to the offering. Accordingly, the offer and sale of these shares was exempt under Rule 506 of Regulation D under the Securities Act.

Following the issuance of common stock as described above, our total issued and outstanding common stock will be 30,653,188 shares.

About EXACTUS, INC. (OTCMKTS:EXDI)

Exactus, Inc. (Exactus), formerly Spiral Energy Tech, Inc., is a life science company. The Company will develop and commercialize Point-of-Care (POC) diagnostics for measuring proteolytic enzymes in the blood based on a detection platform. The Company’s primary business focus will be the development and commercialization of the FibriLyzer and related technology licensed by Exactus. The Company’s products will employ a disposable test biosensor strip combined with a portable hand held detection unit that provides a result in approximately 30 seconds. The Company intends to file to gain regulatory approval and launch its products in the United States and Europe.

An ad to help with our costs